Table 1 The characteristics of patients with ovarian cancer (V5)
From: Correction: In vitro drug testing using patient-derived ovarian cancer organoids
Adjuvant chemotherapy | Survival status | BRCA geme status | Organoid culture | Organoid expansion |
|---|---|---|---|---|
Paclitaxel and carboplatin × 6 cycles, followed by lipodox × 12 cycles, then second debulking then paclitaxel and carboplatin × 6 cycles | Alive | Wild type | Success | No |
Paclitaxel and carboplatin × 9 cycles | Alive | Unexamined | Failed | - |
Paclitaxel and carboplatin × 6 cycles, followed by lipodox × 3 cycles, then gemcitabine and carboplatin × 3 cycles | Expired | Unexamined | Success | Yes |
Not received due to acute stroke | Expired | Unexamined | Success | Yes |
Paclitaxel and carboplatin × 4 cycles, followed by interval debulking, then paclitaxel and carboplatin × 6 cycles, then lipodox, carboplatin and bevacizumab × 6 cycles | Alive | Wild type | Success | Yes |
Paclitaxel and carboplatin × 4 cycles, followed by interval debulking, then paclitaxel and carboplatin × 6 cycles, then lipodox, carboplatin and bevacizumab × 6 cycles | Alive | Wild type | Failed | - |
Paclitaxel and carboplatin × 6 cycles, then lipodox × 6 cycles | Alive | Mutation | Success | Yes |
Paclitaxel and cisplatin × 4 cycles, then lipodox and bevacizumab × 5 cycles, then gemcitabine and bevacizumab × 2 cycles, then topotecan × 8 cycles | Expired | Unexamined | Failed | - |
Paclitaxel, carboplatin and bevacizumab × 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin × 6 cycles, then lipodox × 3 cycles, then gemcitabine × 2 cycles | Expired | Wild type | Success | Yes |
Paclitaxel and carboplatin × 4 cycles | Alive | Unexamined | Success | Yes |
Gemcitabine and carboplatin × 1 cycle | Expired | Unexamined | Success | Yes |
Rejected | Expired | Unexamined | Success | Yes |
Not received | Alive | Unexamined | Success | Yes |
Paclitaxel and carboplatin × 2 cycles, followed by lipodox × 3 cycles, then gemcitabine × 3 cycle | Expired | Wild type | Success | Yes |
Paclitaxel and cisplatin × 6 cycles, then lipodox × 3 cycles, then gemcitabine and cisplatin × 2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin × 2 cycles | Alive | Not received | Success | Yes |
Paclitaxel and carboplatin × 6 cycles, then lipodox and carboplatin × 4 cycles | Alive | Unexamined | Success | No |
Not received | Alive | Unexamined | Success | Yes |
Paclitaxel and carboplatin × 2 cycles, followed by lipodox × 3 cycles, then gemcitabine × 3 cycles | Expired | Wild type | Success | Yes |
Paclitaxel and carboplatin × 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab × 1 cycle, then gemcitabine, carboplatin and bevacizumab × 8 cycles | Alive | Unexamined | Success | Yes |
Paclitaxel and cisplatin × 1 cycle, then gemcitabine and paclitaxel × 3 cycles | Expired | Unexamined | Failed | - |
Paclitaxel and cisplatin × 6 cycles | Alive | Unexamined | Success | Yes |